Breast Cancer Treatment Market Epidemiology Forecast to 2025

Breast Cancer Treatment Market Epidemiology Forecast to 2025 report provide an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China).

June 29, 2017 /MarketersMedia/ —

Breast Cancer (HER2+, HER2-) Epidemiology Forecast to 2025 provides an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year Breast Cancer epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.

Get Discount on Breast Cancer (HER2+, HER2-) Epidemiology Forecast to 2025 99 Pages Report@ http://www.reportsnreports.com/contacts/discount.aspx?name=798545 .

Breast Cancer Epidemiology Forecast to 2025 report provides that Epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60–69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015.
According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent (IARC, 2014). Prolonged exposure to endogenous and exogenous sex hormones; gene mutations; a family history of breast cancer; overweightness and obesity; physical inactivity; a sedentary lifestyle; high alcohol consumption; early age at menarche (younger than 12 years); late age at menopause (older than 55 years); and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density, are all risk factors for breast cancer (ACS, 2011).

You can Request Sample Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=798545 .

The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN. For initial stage at diagnosis throughout the forecast period, 37.82% of diagnosed incident cases of invasive breast cancer were in stage I, 43.19% were in stage II, 14.59% were in stage III, and 4.40% were in stage IV, in the 8MM.

List of Tables:
• Table 1: Risk Factors and Comorbidities for Breast Cancer 12
• Table 2: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%) 17
• Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer 21
• Table 4: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status 22
• Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer 23
• Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status 24
• Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer 25
• Table 8: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis 26
• Table 9: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis 27
• Table 10: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis 28
• Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status 29
• Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis 30
• Table 13: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression 31
• Table 14: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer 53
• Table 15: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 55
• Table 16: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 57
• Table 17: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 59
• Table 18: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N (Row %), 2015 61
• Table 19: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 64
• Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, N, 2015 66
• Table 21: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 68

Purchase This EpiCast Report: Breast Cancer (HER2+, HER2-) – Epidemiology Forecast to 2025 Report at http://www.reportsnreports.com/purchase.aspx?name=798545 .

About Us:
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsnreports.com
Organization: ReportsnReports
Address: Pune
Phone: +1-888-391-5441

Source URL: http://marketersmedia.com/breast-cancer-treatment-market-epidemiology-forecast-to-2025/212141

For more information, please visit http://www.reportsnreports.com/reports/798545-epicast-report-breast-cancer-her2-her2-epidemiology-forecast-to-2025.html

Source: MarketersMedia

Release ID: 212141